JOHN P. UTZ, M.D.; JOHN E. BENNETT, M.D.; MICHAEL W. BRANDRISS, M.D.; WILLIAM T. BUTLER, M.D.; GEORGE J. HILL II, M.D.
This content is PDF only. Please click on the PDF icon to access.
Since 1957 amphotericin B has been employed in the treatment of systemic fungal disease patients being studied at the Clinical Center. Diseases in which the drug has been useful include blastomycosis, histoplasmosis, cryptococcosis, coccidioidomycosis, aspergillosis, sporotrichosis, and candidiasis. The magnitude of effectiveness of the drug is best illustrated by its record in cryptococcal meningitis. Before 1957 and the introduction of amphotericin B, this disease had been universally fatal. At the very least there had not been a report of survival of a single patient. Treatment with amphotericin B has reduced the case fatality
UTZ JP, BENNETT JE, BRANDRISS MW, et al. Amphotericin B Toxicity: Combined Clinical Staff Conference at the National Institutes of Health. Ann Intern Med. 1964;61:334. doi: https://doi.org/10.7326/0003-4819-61-2-334
Download citation file:
Published: Ann Intern Med. 1964;61(2):334.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use